What type of study is this?

This is a Literature Review study.

September 20, 2025Frontline Gastroenterology

Where do novel small molecules fit in the IBD treatment pathway for women of childbearing age?

View Full Paper

Ask AI

Bookmark

Authors

MLMario Andrea LatorreUniversity of Pavia SRSofia RellouLeeds Teaching Hospitals NHS Trust RNRossella E. NappiUniversity of Pavia

Discussion

Member takes

Implication

This review discusses the role of small molecule drugs in inflammatory bowel disease treatment for women, highlighting reproductive safety concerns and shared decision-making.

Key Points

Women of childbearing age may require careful consideration of small molecule drugs in IBD treatment, addressing both safety and counseling needs.
Current evidence supports biologic therapies as low risk during pregnancy, but small molecule drugs raise safety concerns due to limited data and negative animal studies.
Shared decision-making is crucial, as clinicians must not exclude women from treatment options without thorough discussion about reproductive safety.
Clinicians need to stay informed on the evolving evidence regarding small molecule drugs to provide comprehensive therapy options for patients.

Cite This Study

Latorre et al. (2025) studied this question.

synapsesocial.com/papers/68d469ba31b076d99fa66272 https://doi.org/10.1136/flgastro-2025-103182

View Full Paper

Ask AI

Bookmark

Implication

This review discusses the role of small molecule drugs in inflammatory bowel disease treatment for women, highlighting reproductive safety concerns and shared decision-making.

Where do novel small molecules fit in the IBD treatment pathway for women of childbearing age?

Discussion

Member takes

Implication

Key Points

Cite This Study

Where do novel small molecules fit in the IBD treatment pathway for women of childbearing age?

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider